Piramal Pharma Ltd
Piramal Pharma Ltd Share Price Today: Live Updates & Key Insights
Get insights on Piramal Pharma Ltd’s fundamentals, financials, shareholding, peer comparison, corporate actions & performance. Track key metrics, price trends & market sentiment for informed decisions. Explore all data at Motilal Oswal.
Piramal Pharma Ltd Share Price Chart
Piramal Pharma Ltd Fundamentals
Traded Volume: 21,06,643
Market Cap(Cr): 25,040
Avg Traded Price 188.63
1 Year return -23.39%
Upper Circuit 190.2
Lower Circuit 187.6
P/E TTM -1055.00
P/B Ratio 0.00
Traded Value(Cr) 3968.49
EPS TTM -0.179
Book value -0.179
Dividend 0.00%
Piramal Pharma Ltd Share Price Performance
Shows the percentage change in stock price over different time periods
This section highlights Piramal Pharma Ltd stock price performance across key timeframes, including 1-week, 1-month, 3-month, Year-To-Date (YTD), and 1-year returns. It provides insights into the Piramal Pharma Ltd share price history, short-term movements, long-term trends, and overall investor sentiment
1W -2.82%
1M -3.67%
3M -1.78%
1Y -23.39%
YTD -26.57%
Piramal Pharma Ltd Traded Volume Movement
Shows the trading volume over different time periods
This section highlights Piramal Pharma Ltd daily and average traded volumes, offering insights into investor activity and market liquidity. Higher volumes than average often indicate rising interest, news impact, or shifting market sentiment
Yesterday 16.02L
Day Before Yesterday 32.42L
1W Avg 22.70L
1M Avg 32.15L
3M Avg 35.46L
Piramal Pharma Ltd Technical Details
Piramal Pharma Ltd technical indicators, such as support and resistance levels and pivot points, are calculated based on historical price and volume trends. These metrics help traders anticipate possible price movements and make informed trading decisions.
Support 1 187
Support 2 186
Support 3 185
Pivot Point : 189
Resistance 1 190
Resistance 2 191
Resistance 3 193
Piramal Pharma Ltd Corporate Actions
Piramal Pharma Ltd corporate actions include dividends, bonus issues, stock splits, and key company updates that may affect share price and investor sentiment. This section provides timely details on past and upcoming actions, including ex-date, record date, and payout ratio - helping investors make informed decisions based on Piramal Pharma Ltd’s capital allocation strategies.
All
Ex-Date 16-Jul-2025 Type D Description 0.14/share@1.40% Record Date 16-Jul-2025 Ratio 1.40
Ex-Date 12-Jul-2024 Type D Description 0.11/share@1.10% Record Date 12-Jul-2024 Ratio 1.10
Ex-Date 02-Aug-2023 Type R Description /share@5:46% Record Date 02-Aug-2023 Ratio 5:46
Dividends
Announcement Date 16-Jul-2025 Ex Dividend Date 16-Jul-2025 Dividend(%) 1
Announcement Date 12-Jul-2024 Ex Dividend Date 12-Jul-2024 Dividend(%) 1
Bonus
No Bonus has been declared by PPLPHARMA
Splits
No Split has been declared by PPLPHARMA
Others
Ex-Rights Date 02-Aug-2023 Premium(Rs.) 71.00 Ratio 5:46
Piramal Pharma Ltd Peer Comparison
Shows key financial metrics for the company and its peers
This section compares Piramal Pharma Ltd with leading peers in the banking sector based on key metrics such as market capitalization, 1-year return, P/E (TTM), and PB ratio. It helps investors evaluate Piramal Pharma Ltd's relative performance and valuation against major competitors.
Stock Name J B Chemicals & Pharmaceuticals Ltd ₹1729.60 (-1.08%) M. Cap (Cr) 270.85 1 Yr Return (%) +1.62% P/E (TTM) 37.71 PB Ratio 8.43
Stock Name Emcure Pharmaceuticals Ltd ₹1354.60 (-0.52%) M. Cap (Cr) 256.78 1 Yr Return (%) NaN% P/E (TTM) 32.38 PB Ratio 6.23
Stock Name Syngene International Ltd ₹629.25 (-0.84%) M. Cap (Cr) 253.55 1 Yr Return (%) -25.70% P/E (TTM) 54.15 PB Ratio 5.77
Stock Name Piramal Pharma Ltd ₹188.38 (-0.66%) M. Cap (Cr) 250.40 1 Yr Return (%) -23.39% P/E (TTM) -1054.76 PB Ratio 3.16
Stock Name Pfizer Ltd ₹5000.50 (-0.56%) M. Cap (Cr) 228.76 1 Yr Return (%) -2.55% P/E (TTM) 27.26 PB Ratio 5.42
Stock Name ERIS Lifesciences Ltd ₹1666.00 (-0.22%) M. Cap (Cr) 226.94 1 Yr Return (%) +21.88% P/E (TTM) 54.60 PB Ratio 8.19
Stock Name Cohance Lifesciences Ltd ₹589.30 (+1.28%) M. Cap (Cr) 225.45 1 Yr Return (%) -53.76% P/E (TTM) 90.96 PB Ratio 13.19
Piramal Pharma Ltd Cash Flow
Cash flow data provides a view of how money is generated and spent by Piramal Pharma Ltd, across its operating activities, investing activities, and financing activities.
PARTICULARS Operating Activities Mar 2025 548.77 Mar 2024 358.29 Mar 2023 71.52 Mar 2022 255.20 Mar 2021 34.72
PARTICULARS Investing Activities Mar 2025 -549.98 Mar 2024 -635.52 Mar 2023 -435.05 Mar 2022 -1223.02 Mar 2021 -4382.89
PARTICULARS Financing Activities Mar 2025 -61.74 Mar 2024 451.38 Mar 2023 290.12 Mar 2022 905.74 Mar 2021 4494.16
PARTICULARS Net Cash Flow Mar 2025 -64.93 Mar 2024 174.52 Mar 2023 -73.41 Mar 2022 -62.08 Mar 2021 145.99
Piramal Pharma Ltd Shareholding Pattern
This shows the ownership breakdown of Piramal Pharma Ltd, highlighting participation from Foreign Institutional Investors (FII), Mutual Funds, Public, Other Institutions, and Promoters.
Promoter 34.86%
Public 19.46%
Other Institutions 1.78%
FII 30.27%
Mutual Funds 13.11%
About Piramal Pharma Ltd
Piramal Pharma Limited was incorporated on March 4, 2020 as a Public Limited Company and registered with the RoC. The Company offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 17 global facilities and a global distribution network in over 100 countries. It includes an integrated CDMO business, CHG business and ICH business, selling over-the-counter products in India. In addition, it has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market. PPL is a leading pharmaceutical company with global operations, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and global distribution network. It operate under three business verticals - Piramal Pharma Solutions, an integrated contract development and manufacturing organization (CDMO) having a product suite in niche areas such as highly potent Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), antibody drug conjugates, potent sterile injectable, hormonal oral solid dosage forms, biologics and vaccines; Piramal Critical Care, a complex hospital generics (CHG) business in the areas of inhalation anaesthesia, injectable anaesthesia and pain management, intrathecal therapy and other injectable; and India consumer healthcare (ICH) business, selling well-known OTC brands.Apart from this, the Company offers differentiated capabilities in niches areas such as highly potent APIs, antibody drug conjugates, potent sterile injectables, hormonal oral solid dosage forms and biologics and vaccines. The global distribution network gives it access to offer services and products to customers including large global pharma companies, biotech companies, hospitals and institutions.In June 2020, the Company acquired pharmaceutical business from Piramal Enterprises Limited (PEL).In October 2020, the Company received growth equity investment from the Carlyle Group. In It acquired 100% stake in Convergence Chemicals Private Limited (CCPL). It announced expansion for antibody drug conjugates at its Grangemouth (UK) facility and expansion of drug substance capabilities at its Riverview facility (USA).In 2021, it acquired Hemmo Pharmaceuticals Private Limited (HPPL), into the development and manufacturing of peptide APIs. On 7th October 2021, the Composite Scheme of Arrangement, which was entered into between the Company, Piramal Enterprises Limited, Convergence Chemicals Private Limited (CCPL), Hemmo Pharmaceuticals Private Limited (HPPL), PHL Fininvest Private Limited (PFPL) and their respective shareholders and creditors for demerger of Pharma Business from Piramal Enterprises Limited (PEL) to Company, amalgamation of CCPL and HPPL (both being wholly owned subsidiaries of the Company) into Company; and the amalgamation of PFPL (a wholly owned subsidiary of PEL) into PEL became effective from August 18, 2022.In consideration for the demerger, the equity shareholders of PEL as on the demerger record date received 4 equity shares of face and paid-up value of Rs 10 each of the Company for every 1 equity share of face and paid-up value of Rs 2 each held in PEL. i.e. 4:1. Accordingly, the Company was listed on the Stock Exchanges, BSE Limited (BSE) and National Stock Exchange of India Limited 'NSE) on October 19, 2022. In 2022, the Company acquired minority stake in Yapan Bio Private Limited, an India-Based CDMO providing expertise in biologics and vaccines. It launched 26 New products and 37 new SKUs during FY 2023.In FY24, Company launched 27 new products and 24 new SKUs ; launched 21 new products and 31 new SKUs in FY 2025. The Company commenced manufacturing lines at Digwal to supplement Sevoflurane manufacturing capacity at Bethlehem (US) in FY 2025.
Chairperson
Nandini Piramal
Registered office Ground Floor Piramal Ananta, Agastya Corp.Park LBS MargKurl, Mumbai, Maharashtra, 400070
FAX :91-22-3802-3000/4000
Background
Incorporation Year 2020
Face Value ₹10.00
Market Lot 1
FAQs on Piramal Pharma Ltd
How to buy Piramal Pharma Ltd shares on NSE?
To buy Piramal Pharma Ltd shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified.
What is the Piramal Pharma Ltd share price today?
The Piramal Pharma Ltd share price on NSE is ₹188.38 today.
What is the market cap of Piramal Pharma Ltd on NSE?
The company has a market capitalization of ₹25040.38.
What is the PE & PB ratio of Piramal Pharma Ltd?
PE is -1055 and PB is 0.
What is the 52 Week High and Low of Piramal Pharma Ltd shares?
Piramal Pharma Ltd stock price high: ₹283.90 Piramal Pharma Ltd stock price low: ₹181.73.
What can be the future price of Piramal Pharma shares on BSE?
The current price of Piramal Pharma on BSE is 71.51 (24 March 2023, 3:25 PM).
Is it safe to buy Piramal Pharma?
Piramal Pharma, a pharmaceutical company and part of the erstwhile Piramal Group, is a global business with a focus on providing innovative/integrated solutions across the total drug development and manufacturing value chain, right from drug discovery to the commercialisation of medicines.
What is the current market value per shares of Piramal Pharma?
The current price of Piramal Pharma on BSE is 71.51 (24 April 2023, 3:25 PM).
Does Piramal Pharma have any debts?
As of 24 April 2023, Piramal Pharma has debt amounting to Rs. 5016 crores.
Will Piramal Pharma shares price increase?
The ROI on Piramal Pharma stock is -65.32% (YTD).
Should I buy or sell Piramal Pharma?
The 3-month returns on investment (ROI) of Piramal Pharma stock is -35.62%, and YTD is at -65.32%.